We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WETO:NASDAQWetour Robotics Limited Analysis

Data as of 2026-05-10 - not real-time

$0.47

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Wetour Robotics is trading well below its 20‑day (≈$0.52) and 50‑day (≈$0.51) simple moving averages, with the price hovering just above the identified support level of $0.45 and far under the 200‑day SMA of $1.12. Technical indicators such as a RSI of 45 and a bearish MACD histogram reinforce a neutral‑to‑downward bias, while the stock’s volatility of 124% (30‑day) and a beta of 1.42 signal extreme price swings relative to the market. Fundamentally, the company reports a massive revenue decline of 45%, operating margins of –115%, and a net loss reflected in a trailing EPS of –$0.15, compounded by a debt‑to‑equity ratio above 50 and a max drawdown of –90%, indicating severe financial distress. Liquidity is thin, with daily volume (~40k) well below its 3‑month average (~1.87M), and the market sentiment index shows “Extreme Greed,” likely driven by speculative short‑term interest rather than fundamentals. Recent headlines about a Rosen Law Firm‑led securities class‑action investigation add a layer of legal uncertainty, while the company’s rollout of the “Orchestra” platform and a college sponsorship event offer limited positive narrative but are insufficient to offset the prevailing downside risks.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD and price below short‑term SMAs
  • Elevated volatility and beta increasing price swings
  • Pending securities class‑action investigation

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Introduction of the Orchestra platform could unlock future revenue
  • Increasing trading volume suggests growing market interest
  • Continued negative cash flow and high debt constrain upside

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Structural financial deficits and heavy leverage
  • Uncertain path to profitability despite technology focus
  • Potential for turnaround hinges on successful commercialization and financing

Key Metrics & Analysis

Financial Health

Revenue Growth-45.00%
Profit Margin-75.88%
ROE-60.52%
ROA-19.31%
Debt/Equity51.62
P/B Ratio1.3
Op. Cash Flow$-39541028
Free Cash Flow$-35448932
Industry P/E38.4

Technical Analysis

TrendNeutral
RSI45.0
Support$0.45
Resistance$0.63
MA 20$0.52
MA 50$0.51
MA 200$1.12
MACDBearish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta1.42
Volatility124.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.